GPC3-CAR-T cell therapy (China Immunotech Co Ltd)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameGPC3-CAR-T cell therapy (China Immunotech Co Ltd)
Drug Alias NameYTGPC-3YT-GPC-3YT GPC-3YTS-102YTS102
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionWnt signalling pathway inhibitorsAnti-CXCR2Anti-Glypican-3
TargetsGlypican-3C-X-C motif chemokine receptor 2
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesChina Immunotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChina Immunotech Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksN/A